Trial · NCT02856555

Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis

NCT02856555, Phase 2, Completed, Gilead Sciences; results first posted 2020-07-24

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis. Trials, record NCT02856555. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02856555

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis
NCT number: NCT02856555
Status: Completed
Phases: Phase 2
Enrollment: 127 participants, actual
Lead sponsor: Gilead Sciences
Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: Firsocostat, Placebo
First posted: 2016-08-05
Last updated: 2020-07-24
Results first posted: 2020-07-24

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Percentage of Participants Experiencing Treatment-Emergent Adverse Events	First Dose date up to last dose (Week 12) plus 30 days

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Percentage of Participants Experiencing Treatment-Emergent Adverse Events	First Dose date up to last dose (Week 12) plus 30 days	The Safety Analysis Set included participants who received at least 1 dose of study drug.	percentage of participants	NUMBER

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Percentage of Participants Experiencing Treatment-Emergent Adverse Events	Firsocostat 5 mg	70.6	percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events	Firsocostat 20 mg	71.4	percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events	Placebo	61.5	percentage of participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Firsocostat 5 mg	51
Overall Study	STARTED	Firsocostat 20 mg	50
Overall Study	STARTED	Placebo	26
Overall Study	COMPLETED	Firsocostat 5 mg	46
Overall Study	COMPLETED	Firsocostat 20 mg	46
Overall Study	COMPLETED	Placebo	26
Overall Study	NOT COMPLETED	Firsocostat 5 mg	5
Overall Study	NOT COMPLETED	Firsocostat 20 mg	4
Overall Study	NOT COMPLETED	Placebo	0

Source ClinicalTrials.gov

Adverse events66

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Nausea	Gastrointestinal disorders	Firsocostat 5 mg	4	51
other	Nausea	Gastrointestinal disorders	Firsocostat 20 mg	7	49
other	Nausea	Gastrointestinal disorders	Placebo	2	26
other	Diarrhoea	Gastrointestinal disorders	Firsocostat 5 mg	5	51
other	Diarrhoea	Gastrointestinal disorders	Firsocostat 20 mg	6	49
other	Diarrhoea	Gastrointestinal disorders	Placebo	0	26
other	Abdominal pain	Gastrointestinal disorders	Firsocostat 5 mg	2	51
other	Abdominal pain	Gastrointestinal disorders	Firsocostat 20 mg	5	49
other	Abdominal pain	Gastrointestinal disorders	Placebo	1	26
other	Abdominal pain upper	Gastrointestinal disorders	Firsocostat 5 mg	2	51

1 to 10 of 66Source ClinicalTrials.gov

See all 66 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Firsocostat 5 mg	0	51
Total, all-cause mortality	Firsocostat 20 mg	0	49
Total, all-cause mortality	Placebo	0	26
Total, other adverse events	Firsocostat 5 mg	26	51
Total, other adverse events	Firsocostat 20 mg	29	49
Total, other adverse events	Placebo	11	26
Total, serious adverse events	Firsocostat 5 mg	2	51
Total, serious adverse events	Firsocostat 20 mg	2	49
Total, serious adverse events	Placebo	0	26

Source ClinicalTrials.gov

Papers2

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
29705265	DERIVED	PubMed
30059671	DERIVED	PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02856555

GET https://conductscience.org/api/trials/v1/NCT02856555/events?page=2

API reference For AI assistants